Hepatitis B News and Research

Latest Hepatitis B News and Research

HIV test after wrong woman's breast milk given to baby

An Australian hospital has been forced to test a baby for HIV, hepatitis and other infectious diseases after she was given the wrong woman's breast milk.

1 May 2004

Vaccination Week in the Americas in full swing

Reports from the countries say that the immunization campaign has reached some of the most remote areas, including border regions and indigenous communities. The reports also show that the vaccination efforts, which began April 24, are reaching the most vulnerable sectors of the population.

29 Apr 2004

Pennsylvania's restaurants, stadiums, bars and supermarkets are adjusting to revised food safety requirements

Pennsylvania's restaurants, stadiums, bars and supermarkets are adjusting to revised food safety requirements in the Pennsylvania Food Code, according to a specialist in Penn State's College of Agricultural Sciences.

27 Apr 2004

Canadian company requested to ship Dengue Fever test kits to Hong Kong immediately

Medical Services International Inc. has announced that it has been requested to ship VScan Dengue Fever test kits to Hong Kong immediately.

27 Apr 2004

Severe Acute Respiratory Syndrome (SARS) overview

Severe Acute Respiratory Syndrome (SARS) is an atypical form of pneumonia that first appeared in November 2002 in Guangdong Province, China.

24 Apr 2004

WHO calls for Sudan humanitarian assistance

Intensified and urgent action is needed in the Greater Darfur Region of western Sudan to address one of the most severe humanitarian emergencies today. Given the current situation, the humanitarian crisis will last several months.

23 Apr 2004

Respiratory syncytial virus, a common cold virus, can act as a 'hit and hide' virus

An international team of researchers has discovered that respiratory syncytial virus (RSV), a common cold virus causing bronchiolitis in children, can act as a 'hit and hide' virus. It was thought that the virus could only survive in the body for a few days, but these new results show that the virus can survive for many months or years, perhaps causing long-term effects on health, such as damage to the lungs.

23 Apr 2004

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004

Hepatitis B vaccination for inmates

rrectional settings provide a unique opportunity to offer hepatitis B vaccination to a substantial number of high-risk adults who are willing to be vaccinated and who would not otherwise have access to the preventive medicine, according to a new Brown University study of inmates within the Rhode Island Department of Corrections.

23 Apr 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004

PAHO's revolving fund for immunization

A quarter century ago, the Pan American Health Organization (PAHO) and its member countries launched a unique procurement and financing mechanism to buy vaccines, syringes, and "cold chain" equipment – the basic components of their immunization programs.

21 Apr 2004

Can public health promotion beat disease?

Huge efforts are under way to address health problems such as SARS, HIV, diabetes and many other illnesses by developing vaccines or therapeutic drugs.

20 Apr 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

Lack of evidence of sexual transmission of Hepatitis C among monogamous couples

Italian researchers have evaluated the risk of sexual transmission of hepatitis C virus (HCV) infection among 895 monogamous heterosexual partners of HCV chronically infected individuals in a long-term prospective study.

19 Apr 2004

76 million people get sick in US, 300,000 are hospitalized, and 5,000 die from foodborne illness

Foodborne illnesses have a major public health impact in the United States. It is estimated that each year in the United States, 76 million people get sick, more than 300,000 are hospitalized, and 5,000 die as a result of foodborne illnesses, primarily the very young, elderly, and the immunocompromised.

18 Apr 2004

Oral treatment of chronic hepatitis C

Valeant Pharmaceuticals today presented 24-week data from Phase 2 clinical trials of Viramidine, a nucleoside (guanosine) analog Valeant is developing in oral form for the treatment of chronic hepatitis C (HCV) in conjunction with a pegylated interferon.

17 Apr 2004

New forensic tool to detect infectious diseases

Tests for the detection of infectious diseases in North Queensland will be faster and cheaper, thanks to the purchase of new equipment in James Cook University's School of Biomedical Sciences.

16 Apr 2004

Canadian health groups urge ban on exportation of pharmaceutical drugs from Canada to the U.S.

Canadian health groups today called on the Government of Canada to ban the exportation of pharmaceutical drugs from Canada to the U.S. The groups, who represent the interests of millions of Canadian patients, were in Washington to highlight their concerns with Internet pharmacies.

14 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

New AMA guide on treating foodborne illness

In partnership with a national nursing organization and several federal agencies, the AMA released an educational guide on April 7 about how health care professionals should identify and treat foodborne illnesses. "Diagnosis and Management of Foodborne Illnesses: A Primer for Physicians and Other Health Care Professionals" contains charts, scenarios and a continuing medical education section. It is free to health care professionals.

8 Apr 2004